Literature DB >> 3533562

Peripheral vascular effects of bufuralol in hypertensive and normal subjects: a comparison with propranolol and pindolol.

G D Johnston, M B Finch, R G Shanks.   

Abstract

In a double-blind, single oral dose, cross-over study, the effects of bufuralol (60 mg) on heart rate, blood pressure, and peripheral vascular responses were compared with those of propranolol (160 mg), pindolol (10 mg), and placebo in a group of 12 healthy volunteers. All three beta-adrenoceptor antagonists reduced exercise tachycardia, but at the doses chosen the effects of bufuralol were less than those of propranolol. Forearm blood flow was reduced by propranolol and pindolol, but not by bufuralol. The antihypertensive and peripheral vascular effects of bufuralol (30-60 mg bd) were also compared with those of propranolol (40-80 mg bd) in a double-blind crossover study in 10 patients with mild hypertension. Propranolol and bufuralol produced comparable reductions in systemic blood pressure over a two-week period, but the decreases in forearm and finger blood flow were greater with propranolol. These studies suggest that bufuralol is a beta-adrenoceptor antagonist with antihypertensive properties, and that it produces less peripheral vasoconstriction than propranolol or pindolol.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533562     DOI: 10.1007/bf00608210

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  11 in total

1.  Ro 3-4787, a new β-adrenoceptor blocking agent: Studies in normal volunteers.

Authors:  J R Kilborn; P Turner
Journal:  Br J Clin Pharmacol       Date:  1974-04       Impact factor: 4.335

2.  Decrease of peripheral resistance after acute intravenous application of a new beta-receptor blocking agents, bufuralol HCl.

Authors:  D Magometschnigg; J Bonelli; G Hitzenberger; G Kaik; A Korn
Journal:  Int J Clin Pharmacol Biopharm       Date:  1978-02

3.  Intrinsic sympathomimetic activity of beta-adrenoceptor blocking drugs at cardiac and vascular beta-adrenoceptors.

Authors:  T C Hamilton; V Chapman
Journal:  Life Sci       Date:  1978-08-28       Impact factor: 5.037

4.  Bufuralol, a new beta-adrenoceptor blocking agent in a series of benzofuran-2-ethanolamines. Part 2: pharmacology.

Authors:  T C Hamilton; M W Parkes
Journal:  Arzneimittelforschung       Date:  1977-07

5.  A random-zero sphygmomanometer.

Authors:  B M Wright; C F Dore
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

6.  Beta-adrenoceptor blocking drugs and partial agonist activity. Is it clinically relevant?

Authors:  D G McDevitt
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

7.  Relationship between pharmacokinetic and pharmacodynamic behaviour of bufuralol and its metabolite Ro 3-7410 in hypertensive patients.

Authors:  M Eckert; G Cocco; C Strozzi; P Heizmann; C Sfrisi
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

8.  The effects of bufuralol, a beta-adrenoceptor antagonist with predominant beta 2-adrenoceptor agonistic activity, in the cat and the dog.

Authors:  L C Blaber; D T Burden; R Eigenmann; M Gerold
Journal:  J Cardiovasc Pharmacol       Date:  1984 Jan-Feb       Impact factor: 3.105

9.  Beta-adrenoceptor-blocking drugs: current status and the significance of partial agonist activity.

Authors:  W J Louis; J J McNeil; B Jarrott; O H Drummer
Journal:  Am J Cardiol       Date:  1983-07-20       Impact factor: 2.778

10.  Haemodynamic effects of metoprolol and pindolol: a comparison in hypertensive patients.

Authors:  A Svensson; T Gudbrandsson; R Sivertsson; L Hansson
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

View more
  3 in total

1.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

2.  Propranolol use in PHACE syndrome with cervical and intracranial arterial anomalies: collective experience in 32 infants.

Authors:  Denise Metry; Ilona J Frieden; Christopher Hess; Dawn Siegel; Mohit Maheshwari; Eulalia Baselga; Sarah Chamlin; Maria Garzon; Anthony J Mancini; Julie Powell; Beth A Drolet
Journal:  Pediatr Dermatol       Date:  2012-09-20       Impact factor: 1.588

3.  Haemodynamic effects of atenolol, labetalol, pindolol and captopril: a comparison in hypertensive patients with special reference to changes in limb blood flow, heart rate and left ventricular function.

Authors:  D H Roberts; Y Tsao; S F Grimmer; P A Winstanley; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1987-08       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.